Not yet taking people in SpainPhase 1
Tests KK2223 in adults with T-cell non-Hodgkin lymphoma
Tests KK2223, a new drug, in adults with T-cell non-Hodgkin lymphoma.
Plain-language title generated from the registry record
Registry title: A First-in-Human Study of KK2223 in Participants with T-cell Non-Hodgkin Lymphoma
Key facts
- Where
- Barcelona, L'Hospitalet de Llobregat, Madrid, and Pamplona, SpainSee the 4 sites
- Phase
- Phase 1
Where in Spain
- Hospital Clinic de BarcelonaBarcelona, SpainNot yet recruiting
- Institut Catala D'oncologiaL'Hospitalet de Llobregat, SpainNot yet recruiting
- Clinica Universidad de NavarraMadrid, SpainNot yet recruiting
- Clínica Universidad de navarraPamplona, SpainNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Kyowa Kirin Inc.
- Trial code
- NCT07192471EU 2025-522523-96-00
- Record updated
- 15 October 2026